Trial Profile
A 12-month, prospective, randomized, single center, open label pilot study to evaluate the safety and efficacy of Myfortic [mycophenolic acid] in combination with tacrolimus and thymoglobulin [antithymocyte globulin] in early corticosteroid withdrawal.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Apr 2016
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Mycophenolic acid (Primary) ; Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 20 Jul 2008 Actual end date added (January 2008) as reported by ClinicalTrials.gov.
- 20 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 29 Jun 2007 Status changed from recruiting to in progress.